Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: A case/non-case study from the French Pharmacovigilance Database

Acta Diabetologica

Volumn 51, Issue 3, 2014, Pages 491-497

  Faillie, Jean Luc ^a,b   Babai, Samy ^c   Crépin, Sabrina ^d   Bres, Virginie ^a   Laroche, Marie Laure ^d   Le Louet, Hervé ^c   Petit, Pierre ^a   Montastruc, Jean Louis ^b,e   Hillaire Buys, Dominique ^a,f  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d LIMOGES UNIVERSITY HOSPITAL   (France)

^e TOULOUSE UNIVERSITY HOSPITAL   (France)

^f INSERM   (France)

Author keywords

Dipeptidyl peptidase 4 inhibitors; Glucagon like peptide 1 analogs; Pancreatitis; Pharmacovigilance; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; AMINOSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIMONY; AZATHIOPRINE; CODEINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ESTROGEN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; INSULIN; ISONIAZID; LIRAGLUTIDE; MERCAPTOPURINE; METFORMIN; METRONIDAZOLE; ORAL ANTIDIABETIC AGENT; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; SULINDAC; TETRACYCLINE; UNINDEXED DRUG; VALPROIC ACID; VILDAGLIPTIN; GLUCAGON LIKE PEPTIDE 1;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; CONTROLLED STUDY; DATA BASE; DRUG EXPOSURE; DRUG MARKETING; DRUG SURVEILLANCE PROGRAM; FEMALE; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; PRIORITY JOURNAL; RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; CASE CONTROL STUDY; DIABETES MELLITUS, TYPE 2; EPIDEMIOLOGY; FACTUAL DATABASE; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; FRANCE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MALE; MIDDLE AGED; PANCREATITIS; PHARMACOVIGILANCE;

EID: 84905395814     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-013-0544-0     Document Type: Article

References (42)

1. Information for Healthcare Professionals: Exenatide (marketed as Byetta) - 8/2008 Update. Available from http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm, accessed 11 May 2012
2. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC (2011) Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141:150-156
3. Hawkes N (2011) Journal withdraws article after complaints from drug manufacturers. BMJ 342:d2335
4. Hauben M, Patadia V, Gerrits C, Walsh L, Reich L (2005) Data mining in pharmacovigilance: the need for a balanced perspective. Drug Saf 28:835-842 (Pubitemid 41428541)
5. Raschi E, Piccinni C, Poluzzi E, Marchesini G, De Ponti F (2013) The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetol 50:569-577
6. Hauben M, Madigan D, Gerrits CM, Walsh L, Van Puijenbroek EP (2005) The role of data mining in pharmacovigilance. Expert Opin Drug Saf 4:929-948 (Pubitemid 41246142)
7. Wilson AM, Thabane L, Holbrook A (2004) Application of data mining techniques in pharmacovigilance. Br J Clin Pharmacol 57:127-134 (Pubitemid 38223524)
8. Bate A, Evans SJ (2009) Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 18:427-436
9. Moore N, Kreft-Jais C, Haramburu F et al (1997) Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol 44:513-518 (Pubitemid 27485484)
10. Balani AR, Grendell JH (2008) Drug-induced pancreatitis: incidence, management and prevention. Drug Saf 31:823-837
11. Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N (2007) Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf 30:891-898 (Pubitemid 47481444)
12. Hazell L, Shakir SA (2006) Under-reporting of adverse drug reactions: a systematic review. Drug Saf 29:385-396
13. Cohen D (2013) Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds. BMJ 346:f2607
14. Institute for Safe Medication Practices (2013) Perspectives on GLP-1 agents for diabetes. Available from http://www.ismp.org/QuarterWatch/pdfs/ 2012Q3.pdf
15. van der Heijden PG, van Puijenbroek EP, van Buuren S, van der Hofstede JW (2002) On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios. Stat Med 21:2027-2044
16. Galvus (vildagliptin) Summaries of Product Characteristics. EMA 2012. Available from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--- Product-Information/human/000771/WC500020327.pdf
17. Onglyza (liraglutide) Summaries of Product Characteristics. EMA 2012. Available from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--- Product-Information/human/001026/WC500050017.pdf
18. Byetta (exenatide) Summaries of Product Characteristics. EMA 2012. Available from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--- Product-Information/human/000698/WC500051845.pdf
19. Januvia (sitagliptin) Summaries of Product Characteristics. EMA 2012. Available from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--- Product-Information/human/000722/WC500039054.pdf
20. Onglyza (saxagliptin) Summaries of Product Characteristics. EMA 2012. Available from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--- Product-Information/human/001039/WC500044316.pdf
21. Gonzalez-Perez A, Schlienger RG, Rodriguez LA (2010) Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study. Diabetes Care 33:2580-2585
22. Noel RA, Braun DK, Patterson RE, Bloomgren GL (2009) Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 32:834-838
23. Girman CJ, Kou TD, Cai B et al (2010) Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obes Metab 12:766-771
24. Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M (2011) Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 72:905-908
25. Sommet A, Grolleau S, Bagheri H, Lapeyre-Mestre M, Montastruc JL (2008) Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004? Eur J Clin Pharmacol 64:829-834
26. Matveyenko AV, Dry S, Cox HI et al (2009) Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 58:1604-1615
27. Butler PC, Elashoff M, Elashoff R, Gale EA (2013) A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 36:2118-2125
28. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC (2013) Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 62:2595-2604
29. Nauck MA (2013) A critical analysis of the clinical use of in-cretin- based therapies: the benefits by far outweigh the potential risks. Diabetes Care 36:2126-2132
30. Kahn SE (2013) Incretin therapy and islet pathology: a time for caution. Diabetes 62:2178-2180
31. Drucker DJ (2013) Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 62:3316-3323
32. Alves C, Batel-Marques F, Macedo AF (2012) A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract 98:271-284
33. Engel SS, Round E, Golm GT, Kaufman KD, Goldstein BJ (2013) Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies. Diabetes Ther 4:119-145
34. Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317-1326
35. White WB, Cannon CP, Heller SR et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327-1335
36. Dore DD, Bloomgren GL, Wenten M et al (2011) A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 13:559-566
37. Dore DD, Seeger JD, Arnold Chan K (2009) Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 25:1019-1027
38. Garg R, Chen W, Pendergrass M (2010) Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 33:2349-2354
39. Romley JA, Goldman DP, Solomon M, McFadden D, Peters AL (2012) Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population. Diabetes Technol Ther 14:904-911
40. Wenten M, Gaebler JA, Hussein M et al (2012) Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study. Diabet Med 29:1412-1418
41. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB (2013) Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 173:534-539
42. Eurich DT, Simpson S, Senthilselvan A, Asche CV, Sandhu-Minhas JK, McAlister FA (2013) Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ 346:f2267